{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:32:30Z","timestamp":1793158350054,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Key Project of Shaanxi Provincial Natural Science Basic Research Program","award":["2024JC-ZDXM-49"],"award-info":[{"award-number":["2024JC-ZDXM-49"]}]},{"DOI":"10.13039\/501100015401","name":"Key Research and Development Projects of Shaanxi Province","doi-asserted-by":"publisher","award":["2024SF-ZDCYL-02-14"],"award-info":[{"award-number":["2024SF-ZDCYL-02-14"]}],"id":[{"id":"10.13039\/501100015401","id-type":"DOI","asserted-by":"publisher"}]},{"name":"IIT Clinical Research Fund of The Second Afliated Hospital of Xi'an Jiaotong University","award":["No. Z008"],"award-info":[{"award-number":["No. Z008"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Resistance to tyrosine kinase inhibitors (TKIs) poses a significant challenge in the treatment of hepatocellular carcinoma (HCC). Although dysregulation of mitochondrial dynamics has been implicated in the aggressive behaviors of various tumors, the specific role and underlying mechanisms by which this dysregulation contributes to cabozantinib resistance in HCC cells remains insufficiently characterized. By investigating mitochondrial dynamics as central regulators of cabozantinib resistance, this work specifically aims to discover actionable targets for restoring drug sensitivity in treatment-refractory HCC cells. We employed transmission electron microscopy (TEM) and confocal microscopy to analyze mitochondrial morphology in HCC cells resistant to TKIs. Additionally, we utilized an oncogene hydrodynamic injection-induced primary liver cancer mouse model to assess the therapeutic efficacy of combining cabozantinib with other pharmacological agents. Our results demonstrated significant increases in mitochondrial fragmentation, p62 aggregation, and mitophagy in cabozantinib-resistant HCC cells, which correlated with overexpression of c-Myc. Notably, inhibiting mitochondrial fission, p62 aggregation, or autophagy effectively reversed the resistance of HCC cells to cabozantinib. Mechanistically, cabozantinib treatment was shown to induce c-Myc expression, which significantly enhanced mitochondrial fragmentation and p62 aggregation, thereby promoting mitophagy. This mitophagic process selectively eliminated damaged mitochondria, reducing cytochrome C-induced apoptosis in cabozantinib-resistant cells. Ultimately, combining cabozantinib with either the autophagy inhibitor chloroquine or the p62 aggregation inhibitor XRK3F2 resulted in improved anticancer efficacy. In conclusion, c-Myc overexpression facilitates p62 aggregation-mediated mitophagy, leading to cabozantinib resistance in HCC cells. Inhibition of autophagy effectively restores cabozantinib sensitivity in HCC.<\/jats:p>","DOI":"10.1186\/s10020-025-01263-w","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T06:27:30Z","timestamp":1748327250000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Overexpression of c-Myc triggers p62 aggregation-mediated mitochondrial mitophagy in cabozantinib resistance of hepatocellular carcinoma"],"prefix":"10.1186","volume":"31","author":[{"given":"Kaibo","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunong","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunjin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qichao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,27]]},"reference":[{"key":"1263_CR1","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1056\/NEJMoa1717002","volume":"379","author":"GK Abou-Alfa","year":"2018","unstructured":"Abou-Alfa GK, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018;379:54\u201363. https:\/\/doi.org\/10.1056\/NEJMoa1717002.","journal-title":"N Engl J Med"},{"key":"1263_CR2","doi-asserted-by":"publisher","first-page":"100578","DOI":"10.1016\/j.jhepr.2022.100578","volume":"4","author":"M Allaire","year":"2022","unstructured":"Allaire M, et al. What to do about hepatocellular carcinoma: recommendations for health authorities from the international liver Cancer association. JHEP Rep. 2022;4:100578. https:\/\/doi.org\/10.1016\/j.jhepr.2022.100578.","journal-title":"JHEP Rep"},{"key":"1263_CR3","doi-asserted-by":"publisher","first-page":"6927","DOI":"10.1111\/febs.15672","volume":"288","author":"S Berkamp","year":"2021","unstructured":"Berkamp S, Mostafavi S, Sachse C. Structure and function of p62\/SQSTM1 in the emerging framework of phase separation. FEBS J. 2021;288:6927\u201341. https:\/\/doi.org\/10.1111\/febs.15672.","journal-title":"FEBS J"},{"key":"1263_CR4","doi-asserted-by":"publisher","first-page":"105097","DOI":"10.1016\/j.phrs.2020.105097","volume":"160","author":"J Chakraborty","year":"2020","unstructured":"Chakraborty J, Caicci F, Roy M, Ziviani E. Investigating mitochondrial autophagy by routine transmission electron microscopy: seeing is believing? Pharmacol Res. 2020;160:105097. https:\/\/doi.org\/10.1016\/j.phrs.2020.105097.","journal-title":"Pharmacol Res"},{"key":"1263_CR5","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/s41556-018-0133-0","volume":"20","author":"V Eisner","year":"2018","unstructured":"Eisner V, Picard M, Hajnoczky G. Mitochondrial dynamics in adaptive and maladaptive cellular stress responses. Nat Cell Biol. 2018;20:755\u201365. https:\/\/doi.org\/10.1038\/s41556-018-0133-0.","journal-title":"Nat Cell Biol"},{"key":"1263_CR6","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1158\/2159-8290.CD-22-0601","volume":"13","author":"C Glytsou","year":"2023","unstructured":"Glytsou C, et al. Mitophagy promotes resistance to BH3 mimetics in acute myeloid leukemia. Cancer Discov. 2023;13:1656\u201377. https:\/\/doi.org\/10.1158\/2159-8290.CD-22-0601.","journal-title":"Cancer Discov"},{"key":"1263_CR7","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.tox.2016.07.004","volume":"361\u2013362","author":"LE Gomez-Quiroz","year":"2016","unstructured":"Gomez-Quiroz LE, et al. Loss of c-Met signaling sensitizes hepatocytes to lipotoxicity and induces cholestatic liver damage by aggravating oxidative stress. Toxicology. 2016;361\u2013362:39\u201348. https:\/\/doi.org\/10.1016\/j.tox.2016.07.004.","journal-title":"Toxicology"},{"key":"1263_CR8","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1074\/mcp.M110.001776","volume":"9","author":"T Guo","year":"2010","unstructured":"Guo T, et al. Quantitative proteomics discloses MET expression in mitochondria as a direct target of MET kinase inhibitor in cancer cells. Mol Cell Proteom. 2010;9:2629\u201341. https:\/\/doi.org\/10.1074\/mcp.M110.001776.","journal-title":"Mol Cell Proteom"},{"key":"1263_CR9","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1053\/j.gastro.2021.06.008","volume":"161","author":"PK Haber","year":"2021","unstructured":"Haber PK, et al. Evidence-Based management of hepatocellular carcinoma: systematic review and Meta-analysis of randomized controlled trials (2002\u20132020). Gastroenterology. 2021;161:879\u201398. https:\/\/doi.org\/10.1053\/j.gastro.2021.06.008.","journal-title":"Gastroenterology"},{"key":"1263_CR10","doi-asserted-by":"publisher","unstructured":"Ladd AD, Duarte S, Sahin I, Zarrinpar A. Mechanisms of drug resistance in HCC. Hepatology. 2023.\u00a0https:\/\/doi.org\/10.1097\/HEP.0000000000000237.","DOI":"10.1097\/HEP.0000000000000237"},{"key":"1263_CR11","first-page":"5179","volume":"33","author":"SJ Lee","year":"2013","unstructured":"Lee SJ, et al. A survey of c-MET expression and amplification in 287 patients with hepatocellular carcinoma. Anticancer Res. 2013;33:5179\u201386.","journal-title":"Anticancer Res"},{"key":"1263_CR12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.matbio.2020.11.003","volume":"100\u2013101","author":"L Lei","year":"2021","unstructured":"Lei L, Wu Z, Winklhofer KF. Protein quality control by the proteasome and autophagy: A regulatory role of ubiquitin and liquid-liquid phase separation. Matrix Biol. 2021;100\u2013101:9\u201322. https:\/\/doi.org\/10.1016\/j.matbio.2020.11.003.","journal-title":"Matrix Biol"},{"key":"1263_CR13","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.canlet.2018.11.030","volume":"443","author":"R Liu","year":"2019","unstructured":"Liu R, et al. Gankyrin drives metabolic reprogramming to promote tumorigenesis, metastasis and drug resistance through activating beta-catenin\/c-Myc signaling in human hepatocellular carcinoma. Cancer Lett. 2019;443:34\u201346. https:\/\/doi.org\/10.1016\/j.canlet.2018.11.030.","journal-title":"Cancer Lett"},{"key":"1263_CR14","doi-asserted-by":"publisher","unstructured":"Ma Z, et al. Artesunate sensitizes human hepatocellular carcinoma to Sorafenib via exacerbating AFAP1L2-SRC-FUNDC1 axis-dependent mitophagy. Autophagy. 2023;1\u201316. https:\/\/doi.org\/10.1080\/15548627.2023.2261758.","DOI":"10.1080\/15548627.2023.2261758"},{"key":"1263_CR15","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/s41556-018-0176-2","volume":"20","author":"K Palikaras","year":"2018","unstructured":"Palikaras K, Lionaki E, Tavernarakis N. Mechanisms of mitophagy in cellular homeostasis, physiology and pathology. Nat Cell Biol. 2018;20:1013\u201322. https:\/\/doi.org\/10.1038\/s41556-018-0176-2.","journal-title":"Nat Cell Biol"},{"key":"1263_CR16","doi-asserted-by":"publisher","first-page":"5989","DOI":"10.1038\/s41467-021-26295-8","volume":"12","author":"SZ Peng","year":"2021","unstructured":"Peng SZ, et al. Phase separation of Nur77 mediates celastrol-induced mitophagy by promoting the liquidity of p62\/SQSTM1 condensates. Nat Commun. 2021;12:5989. https:\/\/doi.org\/10.1038\/s41467-021-26295-8.","journal-title":"Nat Commun"},{"key":"1263_CR17","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s12943-023-01831-w","volume":"22","author":"Y Ren","year":"2023","unstructured":"Ren Y, et al. Multifaceted role of redox pattern in the tumor immune microenvironment regarding autophagy and apoptosis. Mol Cancer. 2023;22:130. https:\/\/doi.org\/10.1186\/s12943-023-01831-w.","journal-title":"Mol Cancer"},{"key":"1263_CR18","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1136\/gutjnl-2020-320716","volume":"70","author":"R Shang","year":"2021","unstructured":"Shang R, et al. Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma. Gut. 2021;70:1746\u201357. https:\/\/doi.org\/10.1136\/gutjnl-2020-320716.","journal-title":"Gut"},{"key":"1263_CR19","doi-asserted-by":"publisher","first-page":"e12609","DOI":"10.1111\/cpr.12609","volume":"52","author":"J Sheng","year":"2019","unstructured":"Sheng J, et al. Inhibition of PI3K\/mTOR increased the sensitivity of hepatocellular carcinoma cells to cisplatin via interference with mitochondrial-lysosomal crosstalk. Cell Prolif. 2019;52:e12609. https:\/\/doi.org\/10.1111\/cpr.12609.","journal-title":"Cell Prolif"},{"key":"1263_CR20","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/s41422-018-0017-7","volume":"28","author":"D Sun","year":"2018","unstructured":"Sun D, Wu R, Zheng J, Li P, Yu L. Polyubiquitin chain-induced p62 phase separation drives autophagic cargo segregation. Cell Res. 2018;28:405\u201315. https:\/\/doi.org\/10.1038\/s41422-018-0017-7.","journal-title":"Cell Res"},{"key":"1263_CR21","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"key":"1263_CR22","doi-asserted-by":"publisher","first-page":"100976","DOI":"10.1016\/j.drup.2023.100976","volume":"69","author":"S Wang","year":"2023","unstructured":"Wang S, et al. Targeting ACYP1-mediated Glycolysis reverses lenvatinib resistance and restricts hepatocellular carcinoma progression. Drug Resist Updat. 2023;69:100976. https:\/\/doi.org\/10.1016\/j.drup.2023.100976.","journal-title":"Drug Resist Updat"},{"key":"1263_CR23","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","volume":"10","author":"FM Yakes","year":"2011","unstructured":"Yakes FM, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther. 2011;10:2298\u2013308. https:\/\/doi.org\/10.1158\/1535-7163.MCT-11-0264.","journal-title":"Mol Cancer Ther"},{"key":"1263_CR24","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1080\/15548627.2021.2007027","volume":"18","author":"J Yao","year":"2022","unstructured":"Yao J, et al. CDK9 Inhibition blocks the initiation of PINK1-PRKN-mediated mitophagy by regulating the SIRT1-FOXO3-BNIP3 axis and enhances the therapeutic effects involving mitochondrial dysfunction in hepatocellular carcinoma. Autophagy. 2022;18:1879\u201397. https:\/\/doi.org\/10.1080\/15548627.2021.2007027.","journal-title":"Autophagy"},{"key":"1263_CR25","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1002\/hep.24450","volume":"54","author":"H You","year":"2011","unstructured":"You H, Ding W, Dang H, Jiang Y, Rountree CB. c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma. Hepatology (Baltimore MD). 2011;54:879\u201389. https:\/\/doi.org\/10.1002\/hep.24450.","journal-title":"Hepatology (Baltimore MD)"},{"key":"1263_CR26","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1126\/science.1219855","volume":"337","author":"RJ Youle","year":"2012","unstructured":"Youle RJ, van der Bliek AM. Mitochondrial fission, fusion, and stress. Science. 2012;337:1062\u20135. https:\/\/doi.org\/10.1126\/science.1219855.","journal-title":"Science"},{"key":"1263_CR27","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/s41392-021-00790-2","volume":"6","author":"Y Yu","year":"2021","unstructured":"Yu Y, et al. Fis1 phosphorylation by Met promotes mitochondrial fission and hepatocellular carcinoma metastasis. Signal Transduct Target Ther. 2021;6:401. https:\/\/doi.org\/10.1038\/s41392-021-00790-2.","journal-title":"Signal Transduct Target Ther"},{"key":"1263_CR28","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1158\/0008-5472.CAN-19-1389","volume":"80","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, et al. MET Inhibition elicits PGC1alpha-Dependent metabolic reprogramming in glioblastoma. Cancer Res. 2020;80:30\u201343. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-1389.","journal-title":"Cancer Res"},{"key":"1263_CR29","doi-asserted-by":"publisher","first-page":"731527","DOI":"10.3389\/fimmu.2021.731527","volume":"12","author":"S Zhao","year":"2021","unstructured":"Zhao S, et al. Selective inhibitor of the c-Met receptor tyrosine kinase in advanced hepatocellular carcinoma: no beneficial effect with the use of Tivantinib? Front Immunol. 2021;12:731527. https:\/\/doi.org\/10.3389\/fimmu.2021.731527.","journal-title":"Front Immunol"},{"key":"1263_CR30","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.tcb.2023.03.009","volume":"33","author":"XX Zheng","year":"2023","unstructured":"Zheng XX, et al. Mitochondria in cancer stem cells: Achilles heel or hard armor. Trends Cell Biol. 2023;33:708\u201327. https:\/\/doi.org\/10.1016\/j.tcb.2023.03.009.","journal-title":"Trends Cell Biol"},{"key":"1263_CR31","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/S0140-6736(19)30427-1","volume":"394","author":"M Zhou","year":"2019","unstructured":"Zhou M, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990\u20132017: a systematic analysis for the global burden of disease study 2017. Lancet. 2019;394:1145\u201358. https:\/\/doi.org\/10.1016\/S0140-6736(19)30427-1.","journal-title":"Lancet"},{"key":"1263_CR32","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1159\/000530495","volume":"12","author":"J Zhou","year":"2023","unstructured":"Zhou J, et al. Guidelines for the diagnosis and treatment of primary liver Cancer (2022 Edition). Liver Cancer. 2023;12:405\u201344. https:\/\/doi.org\/10.1159\/000530495.","journal-title":"Liver Cancer"}],"container-title":["Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-025-01263-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10020-025-01263-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-025-01263-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T19:01:54Z","timestamp":1748372514000},"score":1,"resource":{"primary":{"URL":"https:\/\/molmed.biomedcentral.com\/articles\/10.1186\/s10020-025-01263-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,27]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1263"],"URL":"https:\/\/doi.org\/10.1186\/s10020-025-01263-w","relation":{},"ISSN":["1528-3658"],"issn-type":[{"value":"1528-3658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,27]]},"assertion":[{"value":"1 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have read and approved the final manuscript. Participants involved in the study have provided their consent for the data to be published.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"209"}}